• Mek ICS issued a correction on Oct. 15, 2026, clarifying that proposed charter amendments include adding in vitro diagnostic device manufacturing.
• The proposed business expansion aims to generate additional manufacturing revenue; shareholders will vote on Oct. 30, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mek ICS Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261015000051), on October 15, 2026, and is solely responsible for the information contained therein.